Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
5
×
boston
5
×
boston blog main
boston top stories
life sciences
national blog main
5
×
clinical trials
deals
editas medicine
gene editing
national top stories
allergan
crispr
cynthia collins
roche
san francisco blog main
abbvie
agios therapeutics
alexion pharmaceuticals
alnylam pharmaceuticals
alzheimer's disease
base editing
biopharma
boehringer ingelheim
branden moriarty
broad institute
cas13
crispr therapeutics
crispr-cas9
david liu
dicerna pharamceuticals
dna
drugs
duchenne
editor
editr
enzyme
europe blog main
europe top stories
fda
What
gene
5
×
editas
editing
medicine
crispr
experimental
medicines
research
roche
therapeutics
therapy
abbvie
allergan
alliance
approval
beam
betting
billion
biopharma
biotech
blessing
bosley
cas
caught
causing
ceo
check
clinical
cusp
deal
depart
dicerna
disease
drug
duchenne
editor
exits
eye
fda
founders
Language
unset
Current search:
gene
×
boston
×
" national blog main "
×
biotech
×
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
5 years ago
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial
@xconomy.com
5 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M
